Assessment of cytokine status in patients with oncological diseases and severe COVID-19

Close metadata

OBJECTIVE:

To evaluate the cytokine status in COVID-19 patients with and without oncological diseases.

MATERIALS AND METHODS

The study included 47 patients (aged 23—80 years) with severe COVID-19. The main group comprised 25 cancer patients, while the control group consisted of 22 patients without cancer. Levels of tumor necrosis factor-alpha (TNF-α) and interleukins (IL) 2, 6, 8, and 10 were assessed.

RESULTS

Post-treatment levels of IL-2, IL-6, and IL-10 were significantly higher in cancer patients compared to the control group: IL-2 (486.2±65.3 vs. 341.2±61.0 pg/ml, p=0.002), IL-6 (4.54±1.4 vs. 2.26±1.7 pg/ml, p=0.001), and IL-10 (6.3±2.1 vs. 5.1±1.6 pg/ml, p=0.002). However, IL-8 (p=0.06) and TNF-α (p=0.08) levels did not differ significantly between the main and control groups. Pathological levels were defined as IL-2 >710 pg/ml, IL-6 >7 pg/ml, IL-8 >62 pg/ml, IL-10 >9.1 pg/ml, and TNF-α >8.1 pg/ml. Cancer patients exhibited a significantly higher frequency of elevated IL-6 (72%), IL-8 (32%), and IL-10 (24%). The frequency of elevated IL-2 and TNF-α levels did not significantly differ between the groups. Deceased patients in the main group had significantly higher levels of IL-2, IL-6, IL-8, IL-10, and TNF-α.

CONCLUSION

Cancer patients with COVID-19 have higher cytokine concentrations compared to non-cancer patients, indicating more pronounced immune dysregulation.

Keywords:

COVID-19

SARS-CoV-2

cytokines

cytokine release syndrome

cancer

Authors:

Vlasenkova A.A.

Petrovsky National Research Centre of Surgery

ORCID: 0009-0009-6529-439X

Alieskerov M.V.

JSC «Medsi Group of Companies» — Clinical Hospital «MEDSI» in Otradnoye

ORCID: 0009-0006-4234-2254

Linnik D.V.

Petrovsky National Research Centre of Surgery

ORCID: 0000-0001-8714-7432

Mochalova A.S.

Petrovsky National Research Centre of Surgery;
JSC «Medsi Group of Companies» — Clinical Hospital «MEDSI» in Otradnoye

ORCID: 0000-0002-7681-5383

Akselrod B.A.

Petrovsky National Research Centre of Surgery

ORCID: 0000-0002-4434-3123

Received:

10.05.2024

Accepted:

31.07.2024

List of references:

World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Geneva: WHO; 2020. Accessed May 12, 2024. https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. https://doi.org/10.1001/jama.2020.1585
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. Respiratory Medicine. 2020;8(5):475-481. https://doi.org/10.1016/S2213-2600(20)30079-5
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal. 2020;55(5):2000547. https://doi.org/10.1183/13993003.00547-2020
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology. 2020;21(3): 335-337. https://doi.org/10.1016/S1470-2045(20)30096-6
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L, Wang H, Chen Z, Li Q, Gale RP. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6): 1637-1645. https://doi.org/10.1038/s41375-020-0836-7
Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9
Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VWT, Curley HM, Fittall MW, Freeman-Mills L, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJ, Lee RJ, McGrath SE, Middleton CP, Murugaesu N, Newsom-Davis T, Okines AF, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Várnai C, Yousaf N, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919-1926. https://doi.org/10.1016/S0140-6736(20)31173-9
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, Maiese A, Savioli G, Volonnino G, Longhitano Y. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Kaunas). 2022;58(2):144. https://doi.org/10.3390/medicina58020144
de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annual Review of Immunology. 2015;33:823-874. https://doi.org/10.1146/annurev-immunol-032414-112227
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46(5):846-848. https://doi.org/10.1007/s00134-020-05991-x
Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine. 2020;26(10):1636-1643. https://doi.org/10.1038/s41591-020-1051-9
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Rüthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Grüner B, Hanses F, Isberner N, Köhler P, Lanznaster J, Merle U, Nadalin S, Piepel C, Schneider J, Schons M, Strauss R, Tometten L, Vehreschild JJ, von Lilienfeld-Toal M, Friedrichs A, Fuhrmann S, Löhnert AY, Mayer K, Ritter V, Trauth J, Wille K, Johne A, Babel N, Bacher P, Bickel M, Bitzer M, Brandt C, Bruns T, Bousset L, Erdmann C, Fätkenheuer G, Gagell C, Hoffmann C, Hoffmann M, Krings A, Körber A, Langeheinecke A, Meise D, Neuwirth M, Nowakowska J, Pletz MW, Pollmer M, Reuter S, Rossi R, Stecher M, Stegemann M, Tacke D, Volk T, Wille A, Witzke O, de With K, Heuschkel C, Schreiber S, Wass S, Jakob CEM, Pilgram L, Harter G, Khodamoradi Y, Pfefferle S, Hippenstiel S, Lütgehetmann M, Schreiber J. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Annals of Hematology. 2021;100(2):383-393. https://doi.org/10.1007/s00277-020-04328-4
Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Reviews. 2010;29(2):317-329. https://doi.org/10.1007/s10555-010-9229-0
Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood. 2017;130(23):2569-2572. https://doi.org/10.1182/blood-2017-08-802413
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-5157. https://doi.org/10.1182/blood-2013-02-485623
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine. 2018;24(6):731-738. https://doi.org/10.1038/s41591-018-0041-7
Sallusto F. Heterogeneity of Human CD4+ T Cells Against Microbes. Annual Review of Immunology. 2016;34:317-334. https://doi.org/10.1146/annurev-immunol-032414-112056
Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(5):2645-2650. https://doi.org/10.1073/pnas.0437939100
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105): 1833-1842. https://doi.org/10.1016/S0140-6736(17)32247-X
Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Frontiers in Immunology. 2022;13:879813.
Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biology. 2020;10(9):200160. https://doi.org/10.1098/rsob.200160

Close metadata